Where semaglutide stands in September 2026

As of mid-September 2026, semaglutide is no longer one drug with one label. Novo Nordisk's molecule is approved in the US under multiple brand names and dosage forms — Ozempic injection, Ozempic tablets, Wegovy injection and Wegovy tablets — covering type 2 diabetes, cardiovascular risk, chronic kidney disease, weight reduction and liver disease ^[1].

What is approved, and for what

Ozempic injection was first approved on December 5, 2017 for blood sugar control in adults with type 2 diabetes ^[1]. It later added an indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and on January 28, 2025 it was approved to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease ^[1]. It comes as 2 mg/3 mL, 4 mg/3 mL and 8 mg/3 mL pens and is given under the skin once weekly, at any time of day, with or without meals ^[1].

The oral side has been reshuffled. Rybelsus tablets (3 mg, 7 mg, 14 mg) were first approved September 20, 2019 ^[1]. A newer "R2" tablet formulation (1.5 mg, 4 mg, 9 mg) was approved December 9, 2024 and was rebranded as Ozempic tablets on January 30, 2026 ^[1]. Novo announced the Ozempic pill on February 4, 2026, with US availability stated for the second quarter of 2026 ^[1]. Ozempic tablets are taken once daily in the morning on an empty stomach ^[1].

On the weight side, Wegovy injection was approved June 4, 2021 and is available in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg pens, with approved uses covering weight reduction in obesity and overweight, cardiovascular risk reduction in obesity or overweight, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) ^[1]. Wegovy tablets were approved December 22, 2025 in 1.5 mg, 4 mg, 9 mg and 25 mg strengths for weight reduction and cardiovascular risk reduction — but not, per this listing, for MASH ^[1].

Price and access moves

Novo lowered the cash price of Ozempic to $499 per month for self-paying patients on August 18, 2025 ^[1]. On February 24, 2026, the company announced what it called a significant reduction in US list prices for Wegovy, Ozempic and Rybelsus ^[1]. The specific new list prices are not given in the source reviewed here. On March 9, 2026, Novo said it was expanding US patient access to FDA-approved semaglutide medicines through Hims & Hers in response to a shift in that company's US GLP-1 business model ^[1].

Why it matters for patients

The practical upshot is that "semaglutide" now means different things depending on the brand, the form and the reason it was prescribed. An injection and a tablet with the same active ingredient can carry different approved uses, different strengths and different instructions — weekly injection versus a daily morning tablet on an empty stomach ^[1]. Coverage decisions, pharmacy stocking and out-of-pocket costs can differ by form too, and the February 2026 list-price cut does not automatically translate into the same change in what any individual pays ^[1].

Safety labeling is unchanged in structure: Ozempic carries a boxed warning for thyroid C-cell tumors, with warnings covering acute pancreatitis, diabetic retinopathy complications, hypoglycemia, acute kidney injury from volume depletion, severe gastrointestinal reactions, serious hypersensitivity reactions, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation ^[1]. Common side effects reported in at least 5% of patients include nausea, vomiting, diarrhea, abdominal pain and constipation, with decreased appetite also listed for the tablets ^[1]. Counterfeits remain a documented concern: Novo warned US consumers about counterfeit Ozempic 1 mg injection in April 2025 ^[1].

What happens next

Novo has said oral semaglutide showed potential as a first oral GLP-1 therapy for children and adolescents with type 2 diabetes, announced April 23, 2026; no US approval for that group is listed ^[1]. Other items often attached to this story — a December decision on CagriSema, generic semaglutide launches outside the US, and current US prescription market share versus Eli Lilly — are not documented in the sources available here, so those specifics cannot be confirmed. Industry pipeline trackers continue to publish periodic GLP-1 updates ^[2].